reason
first
sourc
sarscov
wild
known
explor
rang
speci
suscept
sarscov
infect
may
help
identifi
robert
k
subbarao
sever
acut
respiratori
syndrom
sar
newli
identifi
ill
emerg
southern
china
spread
involv
countri
affect
peopl
caus
nearli
death
worldwid
although
etiolog
agent
rapidli
identifi
previous
unknown
coronaviru
name
sar
coronaviru
sarscov
outbreak
control
public
health
measur
specif
option
avail
prevent
control
human
diseas
past
two
year
number
strategi
vaccin
immunoprophylaxi
investig
anim
model
essenti
preclin
evalu
efficaci
candid
vaccin
antivir
also
need
order
understand
pathogenesi
sar
number
investig
around
world
evalu
sever
differ
anim
speci
model
sar
effort
import
two
natur
reservoir
second
efficaci
vaccin
evalu
human
efficaci
two
anim
model
may
requir
licensur
ideal
anim
model
would
viral
replic
accompani
clinic
ill
patholog
resembl
seen
human
case
sar
howev
consequ
sarscov
infect
differ
anim
model
may
vari
pictur
one
viral
replic
associ
patholog
absenc
clinic
ill
model
viral
replic
present
absenc
clinic
ill
histopatholog
chang
model
demonstr
clinic
ill
patholog
use
studi
diseas
process
well
evalu
intervent
strategi
model
viru
replic
occur
without
clinic
ill
use
vaccin
antivir
studi
case
efficaci
intervent
assess
quantit
virolog
without
accompani
patholog
review
differ
anim
model
report
follow
summari
pro
con
potenti
applic
differ
model
cov
intranas
viru
replic
effici
respiratori
tract
lung
nasal
turbin
peak
viral
replic
day
postinfect
mean
titer
lung
tissu
cultur
infecti
dose
tcid
per
gram
mean
titer
nasal
turbin
tcid
per
gram
follow
administr
tcid
sarscov
viru
clear
respiratori
tract
day
viru
replic
occur
without
sign
ill
weight
loss
ruffl
fur
associ
minim
mild
inflamm
lung
viral
antigen
nucleic
acid
present
epitheli
cell
larg
airway
day
clear
day
sarscov
administ
balbc
mice
oral
viral
nucleic
acid
amplifi
lung
tissu
small
intestin
intranas
administ
sarscov
also
replic
lung
mice
peak
viral
replic
day
clearanc
viru
day
sarscov
infect
balbc
mice
tend
gain
less
weight
mockinfect
mice
mice
also
support
replic
sarscov
selflimit
bronchiol
begin
mix
peribronchiolar
inflammatori
infiltr
progress
bronchiol
migrat
inflammatori
cell
surfac
epithelium
interstiti
inflamm
adjac
alveolar
septa
resolv
complet
next
week
sarscov
infect
mice
develop
sarscov
specif
neutral
antibodi
respons
protect
reinfect
sarscov
antibodi
alon
suffici
transfer
protect
mice
mice
target
defect
immun
system
evalu
order
determin
arm
immun
system
respons
clearanc
sarscov
mice
beig
mice
replic
clear
viru
kinet
mice
without
overt
sign
clinic
diseas
indic
nk
cell
nkt
cell
b
lymphocyt
requir
clearanc
sarscov
lung
mice
young
mice
sarscov
induc
dramat
upregul
subset
inflammatori
chemokin
chemokin
receptor
without
detect
express
classic
proinflammatori
immunoregulatori
cytokin
without
evok
mark
leukocyt
infiltr
lung
taken
togeth
observ
beig
mice
clear
sarscov
normal
proinflammatori
chemokin
may
coordin
rapid
highli
effect
innat
antivir
respons
lung
contrast
young
balbc
mice
support
replic
sarscov
absenc
clinic
ill
pneumon
old
balbc
mice
demonstr
ill
weight
loss
hunch
dehydr
ruffl
fur
day
postinfect
interstiti
pneumon
perivascular
lymphocyt
infiltr
note
day
promin
day
evid
alveolar
damag
seen
multifoc
interstiti
lymphohistiocyt
infiltr
proteinac
deposit
around
alveolar
wall
intraalveolar
edema
day
perivascular
infiltr
persist
chang
associ
alveolar
damag
accompani
prolifer
fibroblast
inflammatori
foci
foci
persist
day
postinfect
may
repres
histolog
correl
fibrosi
scar
seen
highresolut
comput
tomographi
patient
recov
sar
mice
target
disrupt
stat
signal
pathway
develop
sever
sarswhen
lightli
anesthet
balbc
mice
administ
sar
progress
diffus
interstiti
pneumonia
focal
airspac
consolid
unpublish
infiltr
day
postinfect
nodul
dens
mononuclear
inflamm
contain
sarscov
infect
cell
present
liver
stat
knockout
mice
old
balbc
mice
sarscov
replic
higher
titer
young
balbc
mice
old
balbc
mice
recov
infect
balbc
mice
absenc
clinic
ill
histopatholog
evid
mild
inflamm
mice
show
pneumon
mice
recov
infect
develop
neutral
antibodi
respons
protect
subsequ
challeng
antibodi
alon
suffici
protect
mice
replic
sarscov
lower
respiratori
tract
nk
nkt
b
cell
requir
viral
clearanc
efficaci
sever
vaccin
monoclon
antibodi
evalu
balbc
mice
morbid
mortal
pneumon
seen
knockout
mice
old
balbc
mice
infect
sarscov
pathogenesi
diseas
model
investig
infect
balbc
mice
hamster
use
urbani
strain
sarscov
sarscov
isol
patient
use
infect
ferret
mustela
furo
anesthet
ferret
infect
tcid
intratrach
rout
three
six
ferret
letharg
day
postinfect
one
die
day
viru
isol
pharyng
swab
day
postinfect
trachea
lung
tracheobronchi
lymph
node
necropsi
day
administ
dose
tcid
sarscov
viru
replic
effici
lung
titer
tcid
ml
peak
day
postinfect
observ
v
iral
antigen
present
within
cell
inflammatori
pulmonari
intranas
administ
sarscov
replic
effici
respiratori
tract
golden
syrian
hamster
peak
viral
replic
lung
day
mean
titer
approxim
tcid
per
gram
lung
tissu
follow
administr
tcid
clearanc
lung
day
accompani
histopatholog
evid
pneumon
mild
mononuclear
inflammatori
cell
infiltr
note
submucosa
nasal
epithelium
bronchiol
day
postinfect
inflamm
nasal
tissu
resolv
inflammatori
reaction
lung
progress
confluent
area
consolid
involv
surfac
lung
day
postinfect
resolut
day
lung
patholog
associ
overt
clinic
ill
contrast
mice
replic
intranas
administ
sarscov
restrict
respiratori
tract
transient
infect
develop
robust
neutral
antibodi
respons
protect
subsequ
infect
sarscov
clinic
virolog
histopatholog
evid
enhanc
diseas
upon
reinfect
even
presenc
subneutr
level
monoclon
antibodi
sarscov
spike
glycoprotein
cov
diseas
weight
loss
pneumon
begin
acut
bronchiol
summari
sarscov
replic
effici
respiratori
tract
young
viremia
occur
day
follow
infect
viru
detect
liver
spleen
hamster
howev
inflamm
observ
organ
hamster
recov
multifoc
pulmonari
lesion
affect
lung
surfac
area
includ
mild
alveolar
damag
peribronchi
perivascular
lymphocyt
infiltr
ferret
outbr
anim
highli
suscept
virus
acquir
caretak
ferret
use
model
sar
screen
ensur
intercurr
infect
modifi
diseas
associ
sarscov
infect
sarscov
isol
captiv
civet
cat
wild
anim
market
guangdong
provinc
china
sever
civet
cat
detect
antibodi
sarscov
recent
report
wu
et
al
infect
farm
civet
cat
two
strain
sarscov
five
anim
infect
viru
prototyp
viru
isol
civet
cat
anim
infect
sarscov
strain
typic
virus
isol
hong
kong
sar
outbreak
delet
genom
compar
civet
cat
infect
dose
x
tcid
administ
contrast
observ
sarscov
infect
wild
civet
appear
healthi
lethargi
decreas
aggress
note
experiment
infect
farm
civet
cat
day
onward
fever
day
diarrhea
conjunct
anim
anim
leukopenia
day
white
blood
cell
count
normal
day
interstiti
pneumon
alveolar
septal
enlarg
macrophag
lymphocyt
infiltr
note
day
histopatholog
find
reportedli
similar
lesion
describ
sarscov
infect
macaqu
experiment
infect
ferret
viru
isol
throat
anal
swab
anim
day
organ
necropsi
day
n
viral
nucleic
acid
detect
revers
transcriptas
pcr
necropsi
multipl
organ
day
lymph
node
spleen
day
find
experiment
infect
farm
civet
support
epidemiolog
observ
made
wildanim
market
point
civet
potenti
sourc
transmiss
sarscov
anim
human
howev
research
requir
identifi
reservoir
sarscov
natur
among
old
world
monkey
rhesu
cynomolgu
african
green
monkey
experiment
infect
sarscov
use
vaccin
immunogen
andor
efficaci
studi
presenc
extent
clinic
ill
report
studi
consist
attempt
isol
sarscov
tissu
also
variabl
success
tabl
clinic
ill
histopatholog
find
sarscov
infect
cynomolgu
monkey
rang
report
ill
diseas
lethargi
temporari
skin
rash
respiratori
distress
progress
ard
associ
diffus
alveolar
damag
extens
loss
epithelium
alveolar
bronchiolar
wall
thicken
alveolar
wall
hyalin
membran
alveoli
occasion
multinucl
giant
cell
type
pneumocyt
hyperplasia
day
postinfect
clinic
find
sarscov
infect
rhesu
monkey
absent
mild
histopatholog
find
variabl
rang
abnorm
patchi
area
mild
interstiti
edema
alveolar
inflamm
interspers
normal
lung
parenchyma
occasion
area
intraalveolar
edema
inflamm
day
anim
acut
interstiti
pneumonia
day
postinfect
infiltr
lymphocyt
macrophag
nodular
area
lung
age
anim
may
import
determin
outcom
difficult
ascertain
wildcaught
monkey
african
green
monkey
viru
infect
lung
patchi
clear
day
postinfect
titer
viru
respiratori
secret
accur
reflect
titer
viru
recov
trachea
lung
tissu
histopatholog
examin
lung
show
diffus
alveolar
damag
focal
interstiti
pneumon
parallel
viru
titer
resolut
day
postinfect
three
speci
new
world
monkey
also
evalu
model
sar
tabl
although
squirrel
monkey
mustach
tamarin
could
experiment
infect
common
marmoset
develop
fever
wateri
diarrhea
histolog
evid
multifoc
pneumon
hepat
follow
sarscov
infect
evalu
model
warrant
detect
viral
rna
neutral
antibodi
respons
clearli
demonstr
sever
speci
nonhuman
primat
experiment
infect
sarscov
surprisingli
extent
diseas
outbr
anim
variabl
inbr
anim
mice
seen
anim
model
cours
infect
experiment
infect
nonhuman
primat
short
rapid
peak
viral
replic
clearanc
viru
lung
day
differ
speci
histopatholog
chang
also
resolv
rapidli
one
studi
absenc
consist
observ
clinic
ill
rapid
resolut
viral
infect
hepat
day
associ
pulmonari
patholog
may
limit
role
nonhuman
primat
studi
immunogen
vaccin
antivir
rather
pathogenesi
efficaci
studi
speci
support
replic
sarscov
without
accompani
clinic
ill
pulmonari
patholog
model
advantag
disadvantag
tabl
common
theme
number
anim
speci
infect
sarscov
deliv
respiratori
tract
infect
elicit
neutral
antibodi
respons
anim
protect
subsequ
infect
compar
report
reader
bear
mind
viru
use
inoculum
rout
viru
administr
age
anim
may
repres
import
differ
studi
mice
age
anim
use
anesthesia
clearli
affect
cours
infect
characterist
model
taken
consider
determin
util
applic
tabl
list
potenti
use
model
discuss
thank
colleagu
leatric
vogel
elain
lamirand
josephin
mcauliff
brian
murphi
jun
chen
jadon
jackson
aaron
cheng
nih
sherif
zaki
christoph
paddock
jeannett
guarner
wunju
shieh
infecti
diseas
patholog
activ
cdc
marisa
st
clair
bioqual
inc
particip
effort
evalu
sever
anim
model
sar
research
support
part
intramur
research
program
niaid
nih
